読み込み中
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
前日終値
$154.49
+$1.97 · +1.29%
時間外
$154.49
$0.00 · 0.00%
10月9日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
日中レンジ
現在 $154.49
52週レンジ
現在 $154.49
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
25
割高
センチメント
57
まちまち
リスク
47
やや高いリスク
モメンタム
49
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
日中レンジ
現在 $154.49
52週レンジ
現在 $154.49
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 4537.7万 USD | 2993.9万 USD | 2484.4万 USD | 886.9万 USD | 741.9万 USD |
| 販売・一般管理 | 3883.1万 USD | 1005.7万 USD | 682.4万 USD | 395.2万 USD | 237.8万 USD |
| 営業費用 | 8420.8万 USD | 3999.6万 USD | 3166.8万 USD | 1282.1万 USD | 979.7万 USD |
| 受取利息 | — | 373.7万 USD | 7.4万 USD | 2.3万 USD | 5000 USD |
| 支払利息 | — | 2万 USD | 2.5万 USD | 1.6万 USD | — |
| 減価償却費と償却費 | 46.4万 USD | 44.9万 USD | 39.9万 USD | 19.8万 USD | 3万 USD |
| 営業利益 | −8420.8万 USD | −3999.6万 USD | −3166.8万 USD | −1282.1万 USD | −979.7万 USD |
| 純利益 | −7761.1万 USD | −3614.4万 USD | −3163.2万 USD | −1264.8万 USD | −966.6万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$245.83
上昇余地（59.12%）この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR Portfolio Emerging Markets ETFSPEM465.44万0.03%175.23億 USD0.07%$52.21+1.32%
ICBC CSOP S&P New China Sectors ETF3167.HK77.32万0.22%3.58億 HKD1.13%HK$55.98+1.49%
ActivePassive International Equity ETFAPIE64.98万0.06%11.33億 USD0.45%$38.56+0.65%
Fidelity Nasdaq Composite Index ETFONEQ57.15万0.01%109.4億 USD0.21%$107.81+0.63%
State Street SPDR S&P China ETFGXC49.33万0.11%4.46億 USD0.59%$86.47+1.87%
Virtus Biotech Clinical Trials ETFBBC35.03万0.85%4099.65万 USD0.65%$44.1456+2.08%
Even Herd Long Short ETFEHLS19.78万0.34%5883.5万 USD2.62%$25.4482+0.28%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM6.51万0.01%6.89億 USD0.89%$57.70+0.92%State Street SPDR Portfolio Emerging Markets ETFSPEMICBC CSOP S&P New China Sectors ETF3167.HKActivePassive International Equity ETFAPIEFidelity Nasdaq Composite Index ETFONEQState Street SPDR S&P China ETFGXCVirtus Biotech Clinical Trials ETFBBCEven Herd Long Short ETFEHLSMorgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
